'Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued'
Portfolio Pulse from Benzinga Newsdesk
Merck KGaA has decided to discontinue its Phase III trials of xevinapant in locally advanced head and neck cancer due to an interim analysis indicating the trial would not meet its primary objective. This decision affects both the TrilynX and X-Ray Vision studies.
June 24, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck KGaA has discontinued its Phase III trials of xevinapant in locally advanced head and neck cancer. The decision follows an interim analysis indicating the trials would not meet their primary objectives. This could impact investor sentiment negatively in the short term.
The discontinuation of the Phase III trials of xevinapant is a significant setback for Merck KGaA, as it indicates that the drug is unlikely to meet its primary objective. This could lead to negative investor sentiment and a potential short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100